دورية أكاديمية

A real-world pharmacovigilance study of mepolizumab in the FDA adverse event reporting system (FAERS) database.

التفاصيل البيبلوغرافية
العنوان: A real-world pharmacovigilance study of mepolizumab in the FDA adverse event reporting system (FAERS) database.
المؤلفون: Fan Zou, Chengyu Zhu, Siyu Lou, Zhiwei Cui, Dan Wang, Yingyong Ou, Li Wang, Junyou Chen, Yuanbo Lan
المصدر: Frontiers in Pharmacology; 2024, p1-14, 14p
مصطلحات موضوعية: DATABASES, CHURG-Strauss syndrome, DRUG side effects, NASAL polyps, RHINITIS, INHALERS
الشركة/الكيان: UNITED States. Food & Drug Administration
مستخلص: Mepolizumab is primarily used in the treatment of asthma, eosinophilic granulomatosis with polyangiitis, eosinophilia syndrome, and chronic rhinitis with nasal polyps. The information about its adverse drug reactions is mainly derived from clinical trials, and there is a shortage of real-world studies with extensive sample sizes. In this study, the U.S. FDA’s Adverse Event Reporting System (FAERS) database was analyzed to evaluate the side effects of mepolizumab. A total of 18,040 reports of mepolizumab-associated adverse events were identified from the FDA Adverse Event Reporting System database. Multiple disproportionality analysis algorithms were used to determine the significance of these AEs. The study identified 198 instances of mepolizumab-induced AEs, including some important AEs not mentioned in the product labeling. The time to onset of adverse reactions was also analyzed, with a median time of 109 days. Most AEs occurred within the first month of mepolizumab use, but some may still occur after 1 year of treatment. Gender-specific analysis showed different high-risk AEs for females (digestive and neurological side effects) and males (serious adverse effects leading to hospitalization and death). The findings mentioned provide valuable insights on optimizing the use of mepolizumab, enhancing its effectiveness, and minimizing potential side effects. This information will greatly contribute to the practical implementation of the drug in clinical settings. [ABSTRACT FROM AUTHOR]
Copyright of Frontiers in Pharmacology is the property of Frontiers Media S.A. and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
قاعدة البيانات: Complementary Index
الوصف
تدمد:16639812
DOI:10.3389/fphar.2023.1320458